Use of benzodiazepines in hospitals;Utilisation des benzodiazépines à l'hôpital

Medecine et Hygiene

Volumn 60, Issue 2403, 2002, Pages 1574-1577

  Schaad, Nicolas ^a  

^a Pharm Interhospitaliere de la Cote   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CLOBAZAM; CLONAZEPAM; CLORAZEPATE DIPOTASSIUM; DIAZEPAM; LORAZEPAM; LORMETAZEPAM; MIDAZOLAM MALEATE; NCTAMID; NITRAZEPAM; OXAZEPAM; ZALEPLON; ZOLPIDEM TARTRATE; ZOPICLONE;

AMNESIA; DRUG DEPENDENCE; DRUG EFFECT; HOSPITAL CARE; HUMAN; MENTAL DISEASE; PSYCHOMOTOR RETARDATION; SHORT SURVEY; TRANQUILIZING ACTIVITY; TREATMENT CONTRAINDICATION;

EID: 0037019797     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (27)

1. Weinberger DR. Anxiety at the frontier of molecular medecine. N Engl J Med 2001; 344: 1247-9.
2. A receptor subtypes: Dissecting their pharmacological functions. Trends Pharmac Sci 2001; 22: 188-94.
3. Möhler H, et al. A new benzodiazepine pharmacology. J Pharmac Exp Ther 2002; 300: 2-8.
4. A receptor subtype. Proc Natl Acad Sci USA 2001; 98: 6464-9.
5. Ansseau M. La bonne utilisation des benzodiazépines anxiolytiques. Med Hyg 1996; 54: 1502-6.
6. Janicak PG, et al. In: Principles and Practice of Psychopharmacotherapy, 3rd Edition. Philadelphia: Williams and Wilkins, 2001.
7. Venkatakrishnan K, et al. Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol 1998; 18: 256.
8. Schatzberg AF, et al. In: Manual of Clinical Psychopharmacology, 3rd Edition. Washington: American Psychiatric Press, 1997.
9. Chun AHC, et al. Effect of antacids on absorption of clorazepate. Clin Pharmacol Ther 1977; 22: 329-35.
10. Racagni G, et al. In: Pharmacology of anxiolytic drugs. Seattle; Hogrefe and Huber, 1997.
11. Greenblatt DJ, et al. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981; 6: 89-105.
12. Bauer TM, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346: 145-7.
13. Pentikainen PJ. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29: 272-7.
14. Gorski JC, et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47: 1643-53.
15. Pichard L, et al. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23: 1253-62.
16. Gaillot J, et al. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 1987; 10 (Suppl. 1): 7-21.
17. Drover D, et al. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000; 22: 1443-61.
18. Renwick AB, et al. Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28: 337-48.
19. Ray WA, et al. Benzodiazepines of long and short elimination half life and the risk of hip fracture. JAMA 1989; 262: 3303-7.
20. Cummings SR, et al. Risk factors for hip fractures white woman. Study of the osteoporotic fracture research group. N Engl J Med 1995; 332: 767-73.
21. Pierfitte C, et al. Benzodiazepines and hip fractures in elderly people: Case-control study. BMJ 2001; 322: 704-8.
22. Wysowski DK, et al. Sedative-hypnotic drugs and the risk of hip fracture. J Clin Epidemiol 1996; 49: 111-3.
23. Herings RM, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intem Med 1995; 155: 1801-7.
24. Speight TM, et al. In: Avery's drug treatment, 4th Edition. Aukland: ADIS International, 1997.
25. Anonyme. Dépendance aux hypnotiques: zolpidem et zopiclone aussi. La Revue Prescrire 2000; 20: 675-6.
26. Smoller JW, et al. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med 1996; 154: 6-17.
27. Bezchlibnyk-Butler KS. In: Clinical Handbook of psychotropic drugs, 10th Edition. Seattle: Hogrefe and Huber, 2000.